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Summary Xeroderma pigmentosum (XP) is a rare autosomal recessive photosensitive disorder,
which results in multiple face, neck and head basal cell carcinomas (BCCs), squamous
cell carcinomas and melanomas. A 15-year-old boy with XP presented with multiple
facial BCCs previously treated by surgical excision. Standard BCC treatments such as
surgery are not ideal for patients with several facial BCCs because of the risk of
scarring, and the patient refused further surgery. As an alternative, three times weekly
application of imiquimod 5% cream in combination with oral acitretin (20 mg daily)
was prescribed for 4–6 weeks. No adverse events were reported during treatment and
all tumours had resolved at the 6-month follow up visit, highlighting the therapeutic
potential of imiquimod 5% cream.
Introduction
Xeroderma pigmentosum (XP) is an autosomal recessive
photosensitive disorder with an extremely high inci-
dence of ultraviolet (UV)-related skin cancers. It is
associated with impaired ability to repair UV-induced
DNA damage.1,2 It reportedly effects 1 in 250 000
people in Europe and the USA, while its prevalence in
Japan has been documented as 1 in 40 000.2
Clinical management of XP-related skin disorders
consist of early diagnosis followed by a rigorous
programme of sun protection, including avoidance of
unnecessary UV exposure, wearing UV-blocking clo-
thing and use of sun blocks on the skin.2 Failure in
early management of this condition generally results
in basal cell carcinoma (BCC), squamous cell carci-
noma (SCC) and malignant melanomas. Other com-
plications of XP include ocular abnormalities.3 The
carcinomas may be treated by surgery, curettage and
electrodesiccation, cryosurgery, Mohs’ micrographic
surgery, CO2 laser treatment or topical 5-fluoroura-
cil.4–6 These methods, although effective on isolated
carcinomas, are not ideal for treating multiple
tumours, primarily because of a higher risk of causing
disfiguring scarring.
We report a novel method of treating multiple
carcinomas in XP patients with the immune response
modifier, imiquimod 5% cream. Imiquimod, a recom-
mended treatment option for anogenital warts, has been
shown to be effective in treating many other skin
disorders, such as human papilloma virus-associated
warts and skin carcinomas including BCCs.7–10
Case report
A 15-year-old boy presented with XP with associated
multiple BCCs and SCCs on his face. The first appear-
ance of tumours was initially reported at the age of 3
years, and the number and size progressively increased
with advancing age. Previous treatment for these
tumours was surgical excision.
During physical examination, multiple freckles and
dry, atrophic skin were observed on light-exposed
surfaces. Conjunctivitis and ectropion were also evident.
Many keratocanthomas and angiokeratomas were
observed on the trunk and upper and lower extremities.
The 11 tumours (3–6 mm in diameter) proposed for
treatment were located on the face. Some nodules had
superficial ulcerations, and others were covered by
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haemorrhagic crusts (Fig. 1a). In addition, Fig. 1(b,c)
show multiple lesions on the right side of the face and
above the right eyebrow, respectively. Only three of
these tumours were biopsied (one was a BCC and two
were SCCs), although physical and radiological exam-
inations excluded lymphadenopathy and metastatic
involvement, respectively. The patient and his parents
refused surgery as a treatment option for all of the
tumours proposed for treatment. As an alternative, a
combination of oral acitretin (20 mg daily) and topically
applied imiquimod 5% cream was prescribed.
The patient was instructed to apply imiquimod 5%
cream three times a week for 4–6 weeks to two tumours
at a time. The total duration of treatment depended on
the rate at which the tumours resolved. Following
treatment the tumours were confirmed as clinically
clear (Fig. 2a). Perioral tumours located on the delicate
skin around the mouth also completely cleared
(Fig. 2b,c). Tumours located on the right side of the
face (Fig. 2d) and above the right eyebrow (Fig. 2e)
were confirmed to be clinically clear following treat-
ment. During the course of treatment, the patient did
not report any adverse events, although mild local
erythema was observed during application of imiquimod
5% cream. All the tumours were completely cleared at
the 6-month follow-up visit. The patient continues to be
seen every 4 weeks for clinical follow-up and there has
been no recurrence of the tumours.
Discussion
Xeroderma pigmentation (XP) involves DNA repair and
replication deficiencies that predispose homozygous
individuals to a 1000-fold increase in melanoma and
nonmelanoma skin cancers.11 The high incidence of
tumours that develop in sun-exposed areas of the skin of
patients with XP (> 4000 times the incidence in the
general population) has implicated the role of unre-
paired UV-induced DNA lesions in skin carcinogene-
sis.12 This hereditary condition has been found to be
associated with mutations occurring within the tumour
suppressor genes p53 and patched (PTCH).13 Within XP
patients, PTCH mutations represent an earlier event in
BCC development than p53 alterations.14
Clinical management of carcinomas associated with
XP consists of early diagnosis followed by a rigorous
programme of sun protection. Despite extensive precau-
tionary measures, it is inevitable that sufferers of XP will
experience some cutaneous malignancies. However, the
prophylactic usage of oral retinoids, topical retinoids,
(a) (b) (c)
Figure 1 (a) Multiple basal and squamous carcinomas on the face of an XP patient before treatment; (b) multiple lesions on the right
hand side of the face; (c) basal cell carcinoma lesion located above the right eyebrow.
(a) (b) (c)
(e)(d)
Figure 2 (a) Four to 6 weeks after treat-
ment with imiquimod 5% cream, lesions
on the face appear clinically clear and
there is significant improvement and
clearance of perioral lesions located
around the mouth (b, c). (d) Lesions on the
right hand side of the face successfully
cleared following treatment. (e) Clearance
of the BCC lesions above the right
eyebrow.
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local injection of interferon and the external use of
prokaryotic DNA repair enzymes may slow down the
onset of skin cancers.2,15 Conventional methods of
treating BCC, e.g. surgery, cryotherapy and electrodes-
iccation may also be employed in XP-associated
tumours.16 These treatments, although effective in the
short term, may be associated with recurrence and
scarring and may not be feasible for multiple tumours.
In addition to these conventional treatment modalities,
a recent study by Yarosh et al. demonstrated that
topical application of DNA repair enzymes (endonuc-
lease V) to sun-damaged skin of patients with XP
lowered the rate of development of skin cancers,
including BCCs, during a year of treatment.17
The introduction of imiquimod 5% cream as a
treatment for anogenital warts7 has resulted in
researchers identifying its potential use in treating both
viral and nonviral skin conditions, including skin
tumours such as BCC, even where these occur in the
spectrum of hereditary conditions such as Gorlin’s
syndrome.10,18–21 These findings, together with its
successful use in treating facial BCCs in XP patients,
highlights the therapeutic potential of imiquimod 5%
cream for cutaneous oncological conditions.
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